Bausch + Lomb has announced that it has ceased production of its Fluorets product worldwide. The decision to cease production was made solely on commercial grounds and does not relate to regulatory or safety issues in any way. Despite the strongest representations, Bausch + Lomb has indicated that it is unable to reconsider this commercial decision. Bausch + Lomb anticipates that the existing stock of Fluorets will come to an end in May 2013 and it will operate a fair process to ensure equity of supply of remaining stocks in line with previous usage.
Bausch + Lomb will continue to produce minims fluorescein sodium 1% and 2% eye drops solutions and will work with the Optical Confederation to ensure adequate supplies are available. The College of Optometrists will issue clinical advice on their use shortly and have stated that they fully appreciate the enormity of the impact that this will have on clinical and contact lens practice.
The Optical Confederation is also very concerned about the impact this could have on running costs for optical practices and is actively seeking alternative sources of supply although this may not be easy.
ABDO also endorses the additional advice issued by the BCLA, for practitioners who use Fluorets, which can be viewed by selecting the link http://www.bcla.org.uk/en/news/index.cfm/Fluorets